2023 World Conference on Lung Cancer (Posters)-EP08.01. Lymphocyte Count Pre-immunotherapy Predicts Progression-Free Survival in Stage III NSCLC Treated with Chemoradiotherapy and Immunotherapy

EP08.01. Lymphocyte Count Pre-immunotherapy Predicts Progression-Free Survival in Stage III NSCLC Treated with Chemoradiotherapy and Immunotherapy - PDF(Abstract)

Back to course

Pdf Summary

This study investigated the association between peripheral blood lymphocyte counts at different timepoints and clinical outcomes in patients with stage III non-small cell lung cancer (NSCLC) treated with chemoradiotherapy and immunotherapy. A total of 138 patients were reviewed, and lymphocyte counts were recorded at various stages of treatment. The results showed that patients treated with the immunotherapy drug durvalumab had improved progression-free survival (PFS) and overall survival (OS). This improvement in PFS was particularly significant in patients with higher lymphocyte counts prior to receiving durvalumab. The study concludes that circulating lymphocyte counts prior to durvalumab treatment can potentially predict PFS benefit in this cohort of stage III NSCLC patients. Overall, the findings suggest that lymphocyte count could be a biomarker for predicting therapeutic efficacy in this population.

Asset Subtitle

Ashley Horne

Meta Tag

Speaker Ashley Horne

Topic Local-Regional NSCLC: Biomarkers

Keywords

association

peripheral blood lymphocyte counts

clinical outcomes

stage III non-small cell lung cancer

NSCLC

chemoradiotherapy

immunotherapy

durvalumab

progression-free survival

overall survival